Tumor-specific effector CD8+ T lymphocytes, which enable the distinction of relevant tumor antigens within autologous tumor tissues, have been established to be intimately involved in HCC management, not only for tumor growth suppression but also for prolonged progression-free survival, either driven by anti-tumor treatment or occurring naturally [35]. Here, CD8A is linked to neoplasm.